Overview

A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)

Status:
Completed
Trial end date:
2016-07-14
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled, crossover, dose escalation study of gefapixant (AF-219) in participants with Idiopathic Pulmonary Fibrosis (IPF) with persistent cough.
Phase:
Phase 2
Details
Lead Sponsor:
Afferent Pharmaceuticals, Inc.